Does the media refer more to TNGX or BBIO?

In the previous week, BridgeBio Pharma had 9 more articles in the media than Tango Therapeutics. MarketBeat recorded 13 mentions for BridgeBio Pharma and 4 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.90 beat BridgeBio Pharma's score of 0.90 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, EXEL or TNGX?

Exelixis has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.44B 5.71 $782.57M $3.18 17.65 Tango Therapeutics $53.81M 74.51 -$101.59M -$0.85 N/A

Does the media prefer EXEL or TNGX?

In the previous week, Exelixis had 23 more articles in the media than Tango Therapeutics. MarketBeat recorded 27 mentions for Exelixis and 4 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.90 beat Exelixis' score of 0.54 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 12 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 6 Very Negative mention(s) Positive Tango Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TNGX or SMMT more profitable?

Tango Therapeutics' return on equity of -25.75% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tango Therapeutics N/A -25.75% -23.36% Summit Therapeutics N/A -168.94% -141.92%

Does the media favor TNGX or SMMT?

In the previous week, Summit Therapeutics had 5 more articles in the media than Tango Therapeutics. MarketBeat recorded 9 mentions for Summit Therapeutics and 4 mentions for Tango Therapeutics. Summit Therapeutics' average media sentiment score of 1.19 beat Tango Therapeutics' score of 0.90 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TNGX or BMRN?

In the previous week, BioMarin Pharmaceutical had 17 more articles in the media than Tango Therapeutics. MarketBeat recorded 21 mentions for BioMarin Pharmaceutical and 4 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.90 beat BioMarin Pharmaceutical's score of 0.79 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioMarin Pharmaceutical 8 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MDGL or TNGX?

In the previous week, Madrigal Pharmaceuticals had 6 more articles in the media than Tango Therapeutics. MarketBeat recorded 10 mentions for Madrigal Pharmaceuticals and 4 mentions for Tango Therapeutics. Madrigal Pharmaceuticals' average media sentiment score of 0.92 beat Tango Therapeutics' score of 0.90 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tango Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tango Therapeutics (TNGX) Competitors

$23.78 +0.41 (+1.75%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$23.78 -0.01 (-0.02%)

As of 09/11/2026 07:30 PM Eastern

Compare

TNGX vs. BBIO, EXEL, SMMT, BMRN, and MDGL

Should you buy Tango Therapeutics stock or one of its competitors? Tango Therapeutics's main competitors and comparable companies include BridgeBio Pharma (BBIO), Exelixis (EXEL), Summit Therapeutics (SMMT), BioMarin Pharmaceutical (BMRN), and Madrigal Pharmaceuticals (MDGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tango Therapeutics compare to BridgeBio Pharma?

Tango Therapeutics (NASDAQ:TNGX) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

In the previous week, BridgeBio Pharma had 9 more articles in the media than Tango Therapeutics. MarketBeat recorded 13 mentions for BridgeBio Pharma and 4 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.90 beat BridgeBio Pharma's score of 0.90 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

Tango Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-25.75%	-23.36%
BridgeBio Pharma	-97.03%	N/A	-61.19%

Tango Therapeutics currently has a consensus target price of $43.46, indicating a potential upside of 82.77%. BridgeBio Pharma has a consensus target price of $102.61, indicating a potential upside of 41.65%. Given Tango Therapeutics' higher probable upside, analysts plainly believe Tango Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Tango Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. Tango Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$53.81M	74.51	-$101.59M	-$0.85	N/A
BridgeBio Pharma	$713.07M	19.86	-$724.93M	-$3.57	N/A

Summary

Tango Therapeutics and BridgeBio Pharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Tango Therapeutics compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

Exelixis has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

In the previous week, Exelixis had 23 more articles in the media than Tango Therapeutics. MarketBeat recorded 27 mentions for Exelixis and 4 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.90 beat Exelixis' score of 0.54 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	12 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	6 Very Negative mention(s)	Positive
Tango Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 2.6% of Exelixis shares are owned by insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Exelixis has a net margin of 35.33% compared to Tango Therapeutics' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Tango Therapeutics	N/A	-25.75%	-23.36%

Exelixis currently has a consensus price target of $50.07, indicating a potential downside of 10.79%. Tango Therapeutics has a consensus price target of $43.46, indicating a potential upside of 82.77%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tango Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.38
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Exelixis has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.44B	5.71	$782.57M	$3.18	17.65
Tango Therapeutics	$53.81M	74.51	-$101.59M	-$0.85	N/A

Summary

Exelixis beats Tango Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Tango Therapeutics compare to Summit Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Summit Therapeutics had 5 more articles in the media than Tango Therapeutics. MarketBeat recorded 9 mentions for Summit Therapeutics and 4 mentions for Tango Therapeutics. Summit Therapeutics' average media sentiment score of 1.19 beat Tango Therapeutics' score of 0.90 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.24, indicating that its share price is 224% less volatile than the broader market.

Tango Therapeutics has higher revenue and earnings than Summit Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$53.81M	74.51	-$101.59M	-$0.85	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Tango Therapeutics' return on equity of -25.75% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-25.75%	-23.36%
Summit Therapeutics	N/A	-168.94%	-141.92%

Tango Therapeutics currently has a consensus target price of $43.46, indicating a potential upside of 82.77%. Summit Therapeutics has a consensus target price of $25.91, indicating a potential upside of 47.63%. Given Tango Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Tango Therapeutics is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.47

Summary

Tango Therapeutics beats Summit Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Tango Therapeutics compare to BioMarin Pharmaceutical?

Tango Therapeutics (NASDAQ:TNGX) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Tango Therapeutics' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-25.75%	-23.36%
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Tango Therapeutics has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

BioMarin Pharmaceutical has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$53.81M	74.51	-$101.59M	-$0.85	N/A
BioMarin Pharmaceutical	$3.22B	3.95	$348.90M	$0.37	177.51

In the previous week, BioMarin Pharmaceutical had 17 more articles in the media than Tango Therapeutics. MarketBeat recorded 21 mentions for BioMarin Pharmaceutical and 4 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.90 beat BioMarin Pharmaceutical's score of 0.79 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioMarin Pharmaceutical	8 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics currently has a consensus target price of $43.46, indicating a potential upside of 82.77%. BioMarin Pharmaceutical has a consensus target price of $89.17, indicating a potential upside of 35.77%. Given Tango Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tango Therapeutics is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	2.74

Summary

BioMarin Pharmaceutical beats Tango Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Tango Therapeutics compare to Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Tango Therapeutics (NASDAQ:TNGX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

In the previous week, Madrigal Pharmaceuticals had 6 more articles in the media than Tango Therapeutics. MarketBeat recorded 10 mentions for Madrigal Pharmaceuticals and 4 mentions for Tango Therapeutics. Madrigal Pharmaceuticals' average media sentiment score of 0.92 beat Tango Therapeutics' score of 0.90 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Madrigal Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tango Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tango Therapeutics has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Tango Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	$958.40M	12.88	-$288.28M	-$12.89	N/A
Tango Therapeutics	$53.81M	74.51	-$101.59M	-$0.85	N/A

Madrigal Pharmaceuticals currently has a consensus price target of $699.64, suggesting a potential upside of 30.90%. Tango Therapeutics has a consensus price target of $43.46, suggesting a potential upside of 82.77%. Given Tango Therapeutics' higher probable upside, analysts clearly believe Tango Therapeutics is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Madrigal Pharmaceuticals has a beta of -0.98, suggesting that its share price is 198% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

Tango Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Tango Therapeutics' return on equity of -25.75% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%
Tango Therapeutics	N/A	-25.75%	-23.36%

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Tango Therapeutics beats Madrigal Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Tango Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNGX vs. The Competition

Export

Metric	Tango Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.01B	$3.84B	$7.13B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-27.98	14.25	275.24	25.29
Price / Sales	74.51	1,473.06	655.99	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	9.25	15.12	10.33	6.20
Net Income	-$101.59M	-$22.86M	$3.50B	$358.50M
7 Day Performance	5.60%	-4.34%	-3.32%	-2.35%
1 Month Performance	-7.04%	-0.02%	-0.41%	-2.77%
1 Year Performance	264.17%	40.64%	19.21%	7.63%

Tango Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNGX Tango Therapeutics	2.7702 of 5 stars	$23.78 +1.8%	$43.46 +82.8%	+247.7%	$4.01B	$53.81M	N/A	137
BBIO BridgeBio Pharma	3.4571 of 5 stars	$74.62 -0.3%	$101.53 +36.1%	+37.7%	$14.61B	$502.08M	N/A	400	Analyst Forecast
EXEL Exelixis	2.4691 of 5 stars	$58.50 -0.9%	$50.07 -14.4%	+43.6%	$14.48B	$2.32B	18.38	1,077	Trending News Analyst Forecast
SMMT Summit Therapeutics	3.6754 of 5 stars	$17.67 +0.4%	$24.82 +40.5%	-5.6%	$14.07B	N/A	N/A	110	Positive News Analyst Forecast
BMRN BioMarin Pharmaceutical	4.6227 of 5 stars	$65.01 -2.3%	$89.17 +37.2%	+17.5%	$12.60B	$3.22B	175.91	3,221	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNGX) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tango Therapeutics (TNGX) Competitors

TNGX vs. BBIO, EXEL, SMMT, BMRN, and MDGL

How does Tango Therapeutics compare to BridgeBio Pharma?

Summary

How does Tango Therapeutics compare to Exelixis?

Summary

How does Tango Therapeutics compare to Summit Therapeutics?

Summary

How does Tango Therapeutics compare to BioMarin Pharmaceutical?

Summary

How does Tango Therapeutics compare to Madrigal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNGX vs. The Competition

Tango Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tango Therapeutics (TNGX) Competitors

TNGX vs. BBIO, EXEL, SMMT, BMRN, and MDGL

How does Tango Therapeutics compare to BridgeBio Pharma?

Does the media refer more to TNGX or BBIO?

Which has more risk and volatility, TNGX or BBIO?

Is TNGX or BBIO more profitable?

Do analysts prefer TNGX or BBIO?

Do institutionals & insiders hold more shares of TNGX or BBIO?

Which has preferable earnings & valuation, TNGX or BBIO?

Summary

How does Tango Therapeutics compare to Exelixis?

Which has more risk & volatility, EXEL or TNGX?

Does the media prefer EXEL or TNGX?

Do institutionals & insiders believe in EXEL or TNGX?

Is EXEL or TNGX more profitable?

Do analysts recommend EXEL or TNGX?

Which has stronger earnings and valuation, EXEL or TNGX?

Summary

How does Tango Therapeutics compare to Summit Therapeutics?

Do insiders & institutionals believe in TNGX or SMMT?

Does the media favor TNGX or SMMT?

Which has more risk and volatility, TNGX or SMMT?

Which has stronger earnings & valuation, TNGX or SMMT?

Is TNGX or SMMT more profitable?

Do analysts rate TNGX or SMMT?

Summary

How does Tango Therapeutics compare to BioMarin Pharmaceutical?

Is TNGX or BMRN more profitable?

Do institutionals & insiders believe in TNGX or BMRN?

Which has more risk & volatility, TNGX or BMRN?

Which has higher earnings and valuation, TNGX or BMRN?

Does the media refer more to TNGX or BMRN?

Do analysts rate TNGX or BMRN?

Summary

How does Tango Therapeutics compare to Madrigal Pharmaceuticals?

Does the media refer more to MDGL or TNGX?

Which has better valuation and earnings, MDGL or TNGX?

Do analysts recommend MDGL or TNGX?

Which has more risk & volatility, MDGL or TNGX?

Is MDGL or TNGX more profitable?

Do institutionals & insiders hold more shares of MDGL or TNGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNGX vs. The Competition

Tango Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools